Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Quoin Pharmaceuticals Ltd ADR (QNRX)
Quoin Pharmaceuticals Ltd ADR (QNRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,735
  • Shares Outstanding, K 987
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,380 K
  • 60-Month Beta 1.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.37
Trade QNRX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -2.37
  • Number of Estimates 1
  • High Estimate -2.37
  • Low Estimate -2.37
  • Prior Year -4.92
  • Growth Rate Est. (year over year) +51.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.25 +23.08%
on 02/23/24
3.56 -22.19%
on 02/05/24
-0.68 (-19.71%)
since 02/01/24
3-Month
2.25 +23.08%
on 02/23/24
5.41 -48.80%
on 12/04/23
-2.63 (-48.70%)
since 12/01/23
52-Week
2.25 +23.08%
on 02/23/24
12.00 -76.92%
on 07/21/23
-3.83 (-58.03%)
since 03/01/23

Most Recent Stories

More News
Asensus Surgical Continues to Spearhead Innovations and Growth in Surgical Robotics

Asensus Surgical Continues to Spearhead Innovations and Growth in Surgical Robotics

QNRX : 2.77 (+0.73%)
ASXC : 0.3050 (+1.67%)
Asensus Shares First Quarter Results and Future Plans

Asensus Shares First Quarter Results and Future Plans

QNRX : 2.77 (+0.73%)
ASXC : 0.3050 (+1.67%)
Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering

ASHBURN, Va., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty...

QNRX : 2.77 (+0.73%)
Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering

ASHBURN, Va., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty...

QNRX : 2.77 (+0.73%)
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada

Endo's (ENDP) subsidiary, Endo Ventures, signs agreement with Quoin Pharmaceuticals for developing/commercializing the latter's pipeline candidate, QRX003, for treating Netherton syndrome in Canada.

ENDP : 0.2926 (-5.00%)
GLMD : 0.4100 (+3.43%)
VRCA : 5.55 (+5.31%)
QNRX : 2.77 (+0.73%)
Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements

Endo affiliate, Paladin Labs, will commercialize Quoin’s lead asset for Netherton Syndrome in Canada...

QNRX : 2.77 (+0.73%)
ENDP : 0.2926 (-5.00%)
Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

/CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals...

ENDP : 0.2926 (-5.00%)
QNRX : 2.77 (+0.73%)
Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

/PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin...

ENDP : 0.2926 (-5.00%)
QNRX : 2.77 (+0.73%)
Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study

Three Arm, Randomized, Double-Blind, Vehicle Controlled Study Will Test Two Doses of QRX003 Versus Vehicle...

QNRX : 2.77 (+0.73%)
Quoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company...

QNRX : 2.77 (+0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Quoin Pharmaceuticals is a specialty pharmaceutical company focused on rare and orphan diseases. Quoin Pharmaceuticals, formerly known as Cellect Biotechnology Ltd., is based in Tel Aviv.

See More

Key Turning Points

3rd Resistance Point 2.92
2nd Resistance Point 2.86
1st Resistance Point 2.82
Last Price 2.77
1st Support Level 2.71
2nd Support Level 2.65
3rd Support Level 2.60

See More

52-Week High 12.00
Fibonacci 61.8% 8.28
Fibonacci 50% 7.13
Fibonacci 38.2% 5.97
Last Price 2.77
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar